Care of Vulvovaginal Candidiasis in Pregnancy.

Severe VVC is characterized by extensive vulvar erythema, edema, denouncement, and opening organisation. Persons with severe VCC have insufficient responses to parcel courses of either topical or oral therapy. The recommended communicating is either 7 to 14 days of topical azole or 150 mg fluconazole (Diflucan) in two sequential doses (with the angular unit dose 72 distance after the initial dose).
Although the optimal intervention of non-albicans VVC corpse alien, a longer therapy of 7 to 14 days with a non-fluconazole azole drug is recommended. For recurrent non-albicans VVC, 600 mg boric acid in a treat structure administered vaginally once a day for 2 weeks is recommended. Flucytosine (Ancobon) 4% is another alternative, but the device of long-term use of this antifungal drug is variable, and a doctor should be consulted. If non-albicans VVC persistently recurs, 100,000 units of nystatin (Mycostatin) delivered daily by vaginal suppositories as a mending regimen has been recommended. For women with underlying debilitating medical good health, such as uncontrolled diabetes or those on corticosteroid artistic style, it is recommended that therapies be prolonged (i.e., 7–14 days as opposed to 3 days), because these women do not respond as well to short-term therapies. Symptomatic VVC appears to be somewhat more frequent in HIV seropositive women and correlates with the harshness of the immunodeficiency. However, given the oftenness with which recurrent VVC occurs in healthy women, recurrent VVC should not be considered a sentinel sign that justifies HIV investigating. Therapy for VVC in HIV-infected women should not differ from that for women who are not HIV infected.